Leica Biosystems, a Danaher company, has added two Paige digital pathology AI-enabled products from Tempus to its Aperio AI Store, a unified, interoperable digital pathology platform that provides multiple AI-powered applications in a single interface. Aimed at researchers studying cancer, the store is designed to simplify adoption of advanced image analysis and to help turn complex pathology images into research insights.

Two new research applications

The newly available products are:
• Paige PanCancer Detect, a research application designed to identify suspicious areas across more than 40 cancer types, powered by Tempus’ pathology foundation model.
• Paige Prostate, a suite of AI-powered research applications that support the assessment of prostate cancer features in H&E-stained whole slide images. It comprises Paige Prostate Detect, Paige Prostate Grade & Quantify, and Paige Perineural Invasion. Both products are for research use only and are not intended for diagnostic or clinical use.

One workflow for multiple algorithms

The Aperio AI Store brings partner algorithms directly into the Aperio HALO AP software workflow. Instead of navigating separate software interfaces for each algorithm or vendor, users can access a growing selection of curated AI applications through one consistent experience. For laboratories evaluating multiple AI tools across a range of case types, Leica Biosystems said this approach can help reduce complexity and support more efficient adoption.

The store is available exclusively through the Aperio HALO AP image management system, which is developed in partnership with Indica Labs. In the USA, Aperio HALO AP is for research use only and not for use in diagnostic procedures; it is CE-IVDR marked in the EU.

“Nearly one year after launch, the Aperio AI Store is helping move AI in digital pathology from individual applications toward a more connected and scalable experience,” said Naveen Chandra, vice president and general manager of digital pathology at Leica Biosystems. “Tempus brings highly differentiated AI capabilities to our ecosystem, giving laboratories more choice while allowing them to access these technologies within a workflow they already know. This is an important step toward making AI more practical, scalable, and ultimately more impactful in pathology.”

Razik Yousfi, senior vice president and general manager of AI products at Tempus, said: “Our collaboration with Leica Biosystems allows us to bring our AI-enabled computational pathology products directly into the daily workflows of more researchers worldwide. By embedding the Paige offerings into the Aperio HALO AP software ecosystem, we are making advanced image analysis more accessible, seamless, and actionable for oncology research.”

For more information, visit: www.ogt.com
Digital issue: Please click here for more information